Detalhe da pesquisa
1.
Seizure reduction in TSC2-mutant mouse model by an mTOR catalytic inhibitor.
Ann Clin Transl Neurol
; 10(10): 1790-1801, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37545094
2.
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes.
J Med Chem
; 66(13): 9095-9119, 2023 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37399505
3.
Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons.
Commun Biol
; 4(1): 736, 2021 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34127790
4.
Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease.
J Pharmacol Exp Ther
; 333(1): 110-9, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20056779
5.
Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders.
J Med Chem
; 63(3): 1068-1083, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31955578
6.
The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome.
Alzheimer Dis Assoc Disord
; 23(4): 315-8, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19571732
7.
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
J Pharmacol Exp Ther
; 325(1): 146-53, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18199809
8.
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.
Brain Res
; 1216: 92-103, 2008 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-18486110
9.
Kaleidoscope.
AMA J Ethics
; 20(9): E894-896, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30242822
10.
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
J Mol Neurosci
; 31(2): 165-70, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17478890
11.
Antibody against C-terminal Abeta selectively elevates plasma Abeta.
Neuroreport
; 18(3): 293-6, 2007 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-17314674
12.
An Abeta sequestration approach using non-antibody Abeta binding agents.
Curr Alzheimer Res
; 2(2): 265-8, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15974928
13.
Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Neuropharmacology
; 79: 307-13, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24326295
14.
Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400.
FEBS Lett
; 587(22): 3722-8, 2013 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24113653
15.
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.
Exp Neurol
; 205(1): 166-76, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17368447
16.
Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration.
Eur J Neurosci
; 26(9): 2458-68, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17970733
17.
BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
J Neurochem
; 99(6): 1555-63, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17083447
18.
Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant.
Biochem Biophys Res Commun
; 319(3): 733-7, 2004 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-15184044